72 related articles for article (PubMed ID: 21545128)
1. Dynamics of a heparin-binding domain of VEGF(165) complexed with its inhibitor triamterene.
Jeong KW; Lee JY; Lee SA; Yang SP; Ko H; Kang DI; Chae CB; Kim Y
Biochemistry; 2011 Jun; 50(22):4843-54. PubMed ID: 21545128
[TBL] [Abstract][Full Text] [Related]
2. Relationship between structural flexibility and function in the C-terminal region of the heparin-binding domain of VEGF165.
Jeong KW; Jeong MC; Jin B; Kim Y
Biochemistry; 2013 Dec; 52(49):8823-32. PubMed ID: 24274376
[TBL] [Abstract][Full Text] [Related]
3. Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity.
Yang SP; Kwon BO; Gho YS; Chae CB
J Neurochem; 2005 Apr; 93(1):118-27. PubMed ID: 15773911
[TBL] [Abstract][Full Text] [Related]
4. Identification of the heparin-binding region of snake venom vascular endothelial growth factor (VEGF-F) and its blocking of VEGF-A165.
Yamazaki Y; Tokunaga Y; Takani K; Morita T
Biochemistry; 2005 Jun; 44(24):8858-64. PubMed ID: 15952792
[TBL] [Abstract][Full Text] [Related]
5. On the structure, interactions, and dynamics of bound VEGF.
Horta BA; Cirino JJ; de Alencastro RB
J Mol Graph Model; 2008 Apr; 26(7):1091-103. PubMed ID: 18023381
[TBL] [Abstract][Full Text] [Related]
6. The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.
Krilleke D; Ng YS; Shima DT
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1201-6. PubMed ID: 19909247
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein.
Chandrasekaran V; Ambati J; Ambati BK; Taylor EW
J Mol Graph Model; 2007 Nov; 26(4):775-82. PubMed ID: 17560152
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics-based model of VEGF-A and its heparin interactions.
Uciechowska-Kaczmarzyk U; Babik S; Zsila F; Bojarski KK; Beke-Somfai T; Samsonov SA
J Mol Graph Model; 2018 Jun; 82():157-166. PubMed ID: 29738889
[TBL] [Abstract][Full Text] [Related]
9. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease.
Yang SP; Bae DG; Kang HJ; Gwag BJ; Gho YS; Chae CB
Neurobiol Aging; 2004 Mar; 25(3):283-90. PubMed ID: 15123332
[TBL] [Abstract][Full Text] [Related]
10. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites.
Mitsi M; Hong Z; Costello CE; Nugent MA
Biochemistry; 2006 Aug; 45(34):10319-28. PubMed ID: 16922507
[TBL] [Abstract][Full Text] [Related]
11. Backbone dynamics of the C-terminal SH2 domain of the p85alpha subunit of phosphoinositide 3-kinase: effect of phosphotyrosine-peptide binding and characterization of slow conformational exchange processes.
Kristensen SM; Siegal G; Sankar A; Driscoll PC
J Mol Biol; 2000 Jun; 299(3):771-88. PubMed ID: 10835283
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.
Patel NS; Mathura VS; Bachmeier C; Beaulieu-Abdelahad D; Laporte V; Weeks O; Mullan M; Paris D
J Neurochem; 2010 Jan; 112(1):66-76. PubMed ID: 19818105
[TBL] [Abstract][Full Text] [Related]
13. Identification and localization of heparin-binding region of snake venom VEGF and its blocking of VEGF-A165.
Tokunaga Y; Yamazaki Y; Morita T
Pathophysiol Haemost Thromb; 2005; 34(4-5):194-6. PubMed ID: 16707926
[TBL] [Abstract][Full Text] [Related]
14. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.
Lee JH; Canny MD; De Erkenez A; Krilleke D; Ng YS; Shima DT; Pardi A; Jucker F
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18902-7. PubMed ID: 16357200
[TBL] [Abstract][Full Text] [Related]
15. Backbone dynamics, amide hydrogen exchange, and resonance assignments of the DNA methylphosphotriester repair domain of Escherichia coli Ada using NMR.
Habazettl J; Myers LC; Yuan F; Verdine GL; Wagner G
Biochemistry; 1996 Jul; 35(29):9335-48. PubMed ID: 8755711
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols.
Gandhi NS; Mancera RL
J Chem Inf Model; 2011 Feb; 51(2):335-58. PubMed ID: 21299226
[TBL] [Abstract][Full Text] [Related]
17. The structure of truncated recombinant human bile salt-stimulated lipase reveals bile salt-independent conformational flexibility at the active-site loop and provides insights into heparin binding.
Moore SA; Kingston RL; Loomes KM; Hernell O; Bläckberg L; Baker HM; Baker EN
J Mol Biol; 2001 Sep; 312(3):511-23. PubMed ID: 11563913
[TBL] [Abstract][Full Text] [Related]
18. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
19. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
20. The C-terminus of viral vascular endothelial growth factor-E partially blocks binding to VEGF receptor-1.
Inder MK; Wise LM; Fleming SB; Mercer AA
FEBS J; 2008 Jan; 275(1):207-17. PubMed ID: 18076652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
